The recommendations surround important updates to standard criteria that are commonly used despite being decades old.

Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory ...

Crohn’s and Colitis Canada’s Grants-in-Aid of Research Program supports investigator-driven research with defined objectives that advance understanding of Crohn’s disease, ulcerative colitis and ...

Montai has dosed the first participants in a Phase 1 trial of MTAI-1025, a novel oral NRF2 agonist for the treatment of ulcerative colitis.

Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative ...

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease Three moderated posters to showcase gut-targeted exposure, favorable ...

USA: In the phase IIb RELIEVE UCCD trial, investigational duvakitug improved clinical remission rates in patients with ulcerative colitis and endoscopic response rates in those with Crohn’s disease.

Ulcerative colitis has long been framed as a disease of overactive immunity, a condition in which the immune system attacks ...

Today marks 10 years since I developed ulcerative colitis.10 years.10 years.When I think about that, I feel a strange sensation.These past 10 years, I haven't been healthy the whole time.And even now, ...

Click here for the previous article↓ Nothing particularly eventful happened during my hospitalization. My usual attending physician came to check on me and said we would try a new medication after ...

Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than ...